HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Adenosine-5'-(N-ethylcarboxamide) (NECA)

Subscribe to New Research on Adenosine-5'-(N-ethylcarboxamide)

A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.

Also Known As:

NECA; Adenosine-5'-N-ethyluronamide; N6-Ethyl-carboxamido Adenosine; 5' N Ethylcarboxamidoadenosine; Adenosine 5' N ethyluronamide; Adenosine, N6-Ethyl-carboxamido; N Ethylcarboxamidoadenosine; N6 Ethyl carboxamido Adenosine; 5'-N-Ethylcarboxamidoadenosine; N-Ethylcarboxamidoadenosine

Networked: 170 relevant articles (7 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cohen, Michael V: 4 articles (09/2007 - 03/2004)
2.	Downey, James M: 4 articles (09/2007 - 03/2004)
3.	Krieg, Thomas: 3 articles (01/2015 - 03/2004)
4.	Yang, Xi-Ming: 3 articles (09/2007 - 03/2004)
5.	Cui, Lin: 3 articles (09/2007 - 03/2004)
6.	Wang, Bo: 2 articles (10/2012 - 05/2012)
7.	Khunamornpong, Surapan: 2 articles (01/2012 - 11/2011)
8.	Kovárů, Hana: 2 articles (01/2012 - 01/2011)
9.	Utaipat, Utaiwan: 2 articles (01/2012 - 11/2011)
10.	Settakorn, Jongkolnee: 2 articles (01/2012 - 11/2011)

Related Diseases

1.	Seizures (Seizure) 01/01/2015 - "On the other hand, the auxiliary application of NECA dramatically decreased the frequency of generalized seizures and seizure stage, shortened duration of afterdischarge and generalized seizures, as well as the elevated the afterdischarge threshold and generalized seizures threshold. " 12/01/1989 - "NECA, the most potent compound evaluated, completely prevented seizures at doses greater than or equal to 6.8 pmol. " 11/01/1987 - "NECA effects were statistically significant only in CN-kindled seizures. " 12/29/1995 - "2HE-NECA and NECA maintained their protective activity against pentylenetetrazole-induced seizures (63% or 60% vs. 60% or 58% in acute studies, respectively). " 07/13/1990 - "Anticonvulsant effect of N-ethylcarboxamidoadenosine against kainic acid-induced behavioral seizures in the rat prepiriform cortex."
2.	Catalepsy 01/13/2014 - "Haloperidol and NECA-induced mice pre-treated with PTTP at 10mg/kg showed attenuation in catalepsy and akinesia without significant neurotoxicity in rotarod test at 20mg/kg. Essentially, novel compound demonstrated remarkable potential as A2AR antagonist in the therapy of PD." 05/01/1998 - "The effect of serotonergic agents was studied on the adenosine A2 receptor agonist NECA-induced catalepsy in mice. " 10/29/1997 - "Naloxone inhibited the catalepsy induced by morphine or morphine + NECA but not that induced by NECA alone. " 01/01/1993 - "The adenosine agonists 5-N'-ethylcarboxamide-adenosine (NECA), N6-phenylisopropyladenosine (PIA) and N6-cyclohexyladenosine (CHA) induced dose dependent catalepsy. " 01/01/1993 - "The A1 adenosine antagonist 8-phenyltheophylline (8-PT) potentiated catalepsy induced by NECA, R-PIA and CHA. "
3.	Memory Disorders (Memory Loss) 11/01/2007 - "ASP5854 ameliorated A(2A) agonist 2-[p-(2-carboxyethyl) phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the minimum effective doses of 0.32 and 0.1 mg/kg, respectively, and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg. In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated l-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg. ASP5854 also significantly restored the striatal dopamine content reduced by 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg. Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A(2A) antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not. "
4.	Hemorrhage 06/01/1991 - "Prostaglandin E1, like NECA, also caused retinal vasodilation and hemorrhages. " 06/01/1991 - "These data suggest that stimulation of intracellular cyclic AMP accumulation may be a common feature of mediators that cause breakdown of the blood-retinal barrier, but there may be another as yet unexplained feature shared by PGE1 and NECA that makes them particularly effective and capable of causing retinal vasodilation and hemorrhages."
5.	Contracture 06/01/1999 - "The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 +/- 7.1 mm Hg (p < 0.01); 46.1 +/- 7.8 mm Hg (p < 0.01); 46.9 +/- 5.5 mm Hg (p < 0.01); and 59.3 +/- 6.7 mm Hg (p < 0.05) with 10(-4) M adenosine, 5 x 10(-6) M NECA, 10(-6) M CGS 21680, and 10(-7) M 2-hexynylNECA, respectively, versus 77.6 +/- 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 +/- 1.6, 22.2 +/- 7.9, 14.2 +/- 3.3, and 14.1 +/- 4.5 U/gww in treated hearts vs. 34.6 +/- 7.2 U/gww in controls; p < 0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 +/- 0.5, 10.4 +/- 0.6, 9.8 +/- 0.5, and 10.5 +/- 0.5 micromol/gdw in treated hearts vs. 7.6 +/- 0.2 micromol/gdw; p < 0.05]. "

Related Drugs and Biologics

1.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
2.	Adenosine
3.	Purinergic P1 Receptors (Adenosine Receptor)
4.	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosine
5.	Adenosine A2A Receptor (Adenosine A2A Receptors)
6.	Pentylenetetrazole (Metrazol)
7.	Adenosine A1 Receptor
8.	P-2 (P 2)
9.	Cyclic AMP (AMP, Cyclic)
10.	Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1.	Injections
2.	Organ Transplantation
3.	Resuscitation
4.	Cardiopulmonary Bypass (Heart-Lung Bypass)